Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Cerebellar-parietal dysfunctions in multiple sclerosis patients with cerebellar signs.
Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin.
Physical fitness assessment in multiple sclerosis patients: A controlled study.
Neuromyelitis optica in a patient with pemphigus foliaceus.
A review of the sheep-multiple sclerosis connection.
FDA approval of Isentress (raltegravir)
Development and assessment of a website presenting evidence-based information for people with multiple sclerosis: the IN-DEEP project.
Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial.
Immune activation, viral gene product expression and neurotoxicity in the HIV-1 transgenic rat.
The recurrent Guillain-Barré syndrome: a long-term population-based study.
A CB(1)/CB(2) receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin.
Functional identification of neural stem cell-derived oligodendrocytes.
Transplantation of Placenta-Derived Mesenchymal Stem Cells in the EAE Mouse Model of MS.
Cell intrinsic role of NF-κB-inducing kinase in regulating T cell-mediated immune and autoimmune responses.
Sub-Chronic Neuropathological and Biochemical Changes in Mouse Visual System after Repetitive Mild Traumatic Brain Injury.
ATX-MS-1467 in Multiple Sclerosis
Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.
Inhibition of glial proliferation, promotion of axonal growth and myelin production by synthetic glycolipid: A new approach for spinal cord injury treatment.
Secukinumab: first global approval.
Human T cell expansion and experimental autoimmune encephalomyelitis inhibited by Lenaldekar, a small molecule discovered in a zebrafish screen.
Idiopathic inflammatory demyelinating diseases of the central nervous system in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors and survival.
The Diagnostic Accuracy of Static Posturography in Predicting Accidental Falls in People With Multiple Sclerosis.
Extreme Stability of Chitotriosidase in Cerebrospinal Flulid makes it a Suitable Marker for Microglial Activation in Clinical Trials.
B-50Alternate Scoring of the Paced Auditory Serial Addition Test (PASAT): Evaluating Strings of Consecutive Correct Responses as Predictors of Cognitive Functioning in Patients with Multiple Sclerosis.
Pages
« first
‹ previous
…
212
213
214
215
216
217
218
219
220
…
next ›
last »